Nigeria is forging ahead with its hydrochloroquine trials for the treatment of covid-19.
This is inspite of the announcement by the World Health Organisation suspending the drug test.
On Monday, Tedros Ghebreyesus, the WHO director-general, cited the study published by The Lancet, which had examined the effects of the use of hydroxychloroquine alone or when used with a macrolide, and reported a higher mortality rate.
Read Also
- NAFDAC Warns Against Circulation of Substandard, Unregistered Edible Oils
- Enforcement of Total Ban on Alcohol Sachets, Small Bottles to Begin in January 2026 - NAFDAC
- Customs, NAFDAC Strengthen Partnership to Safeguard Public Health, National Security
- Pharmaceutical Products Import Drops To 60 Percent - NAFDAC DG
But the NAFDAC DG said there is data to prove that chloroquine is effective in treating COVID-19 patients, particularly at the “mild stage” of the virus.
She said Nigeria would continue its clinical trials which may take three to four months.
